Introduction
Cytotoxic T-cell responses against virus-infected cells are of key importance in the clearance and control of most virus infections [1] . Cytotoxic T lymphocytes (CTL) recognize viral peptides presented by major histocompatibility complex (MHC) class I molecules at the surface of infected cells [2] [3] [4] [5] [6] . CTL responses against many viruses involve recognition of a single or few immunodominant viral epitopes [7] [8] [9] . However, studies of CTL specific for HIV-1 have shown that multiple epitopes of all proteins of HIV-1 may serve as targets and that these epi-topes can be presented by the same restricting human leukocyte antigen (HLA) class I molecule [10] [11] [12] [13] , To date there has been no systematic study to determine to which of these peptides an HIV-seropositive individual responds. The initial vigour of the CTL response against HIV-1 in infected individuals is shown by CTL activity of freshly isolated peripheral blood mononuclear cells (PBMC) without restimulation [13] . Despite these initial CTL responses, HIV-1 infection nevertheless leads to virus persistence and eventually to deterioration of humoral and ceUular immune responses [14] [15] [16] , resulting in AIDS [17] .
One role of CTL in eradicating HSV-infected human cells was shown in studies in which in vitro HIV-1 replication was controlled by MHC class I-restricted CTL [18, 19] . Studies of SIV-infected macaques showed that animals with broad CTL activity were able to control disease in contrast to SIV-infected macaques with low CTL activity [20, 21] . In HIV-1-infected asymptomatic individuals effective CTL responses were found against relatively or highly conserved sequences of HIV-1 Gag [10, 22, 23] , reverse transcriptase (RT) [24] and Nef [25] .
HIV-1 exhibits sequence variation due to error-prone RT, recombination and the absence of an error-correction system [26] . Consequent to this lack of control, the number of virus variants increases with disease progression [27] . In longitudinal studies a decline or loss of CTL responses to a particular epitope was found associated with the emergence of epitope-loss virus variants [28, 29] . Also, in a comparison of CTL reactivity to an epitope of one particular HIV-1 virus with natural variants of this epitope in other HIV-1 viruses, a decrease or absence of cytotoxicity against peptide-incubated targets was observed [30] . These results combined with those of CTL studies in long term asymptomatic individuals suggest that CTL capable of controlling HIV-1 infection are directed against epitopes that are not readily prone to mutation. Strong and sustained CTL responses against these highly conserved sequences might enable the infected host to effectively control the spread of virus or to establish at least a low grade of infection so that disease progression is delayed.
Conservation of protein sequences may reflect functional importance in the life cycle of the virus. Since HLA-A*0201 is found at high frequency in all human races [31], we selected HLA-A*0201-binding peptides that were completely conserved among different HIV-1 virus strains. In vitro induction of peptide-specific class I-restricted primary CTL responses has been achieved in the mouse [32, 33] This study demonstrates that novel CTL epitopes in conserved HIV sequences can be identified by the strategy of in vitro primary immune response induction by HLA-A*0201 motif-bearing peptides with proven binding ability to HLA-A*0201.
Materials and methods

Cell lines and recombinant vaccinia viruses
The processing defective T2 cell line, which expresses low levels of surface HLA-A*0201, was a gift from Dr P. Cresswell (Yale University, New Haven, Connecticut, USA . Virus strains not full-length sequenced or the highly divergent Cameroonian isolates were not included. All predicted high-scoring peptides were compared and those sequences with anchor residues on both anchor positions and completely conserved among all 14 strains were synthesized as described previously [34] . Peptides with a FI>0.5 were considered to bind to HLA-A*0201. Subsequent serial dilutions of the concentration of peptide were used to determine the concentration needed to upregulate HLA-A*0201 to half maximum fluorescence on the T2 cell line.
Primary CTL induction
The in vitro CTL response induction method recently published [34] was modified as follows. T2 cells were loaded with 100|ig/mi peptide overnight at 37°C and subsequently treated with 50 Hg/ml Mitomycin-C (Kyowa Co. Ltd, Tokyo, Japan). After 2 h the cells were washed twice and used as antigen-presenting cells by cocultivation with HLA-A*0201 -positive PBMC of a healthy HIV-1-seronegative donor at a T2-to-PBMC ratio of 1:4. Cells were cultured for 10 days in 2ml standard medium [RPMI-1640 Dutch modification (Gibco, Paisley, Scotland, UK) containing L-glutamine, antibiotics, 15% pooled human serum] and 40 Hg/ml peptide in 24-well Costar plates (Costar, Cambridge, Massachusetts, USA) at a density of 2 million cells/well. Responder cells were harvested and depleted of CD4+ T cells using CD4+ magnetic beads (Dynal A.S, Oslo, Norway). Two million CD4-depleted responder cells were restimulated with a feeder-mix consisting of 1x106 irradiated (3000 rad) autologous PBMC and 2xl0 5 irradiated (10 000 rad) autologous B-LCL. Feeder cells were sensitized with 50 pig/ml peptide in serum-free Iscove's modified Dulbecco's medium for 2 h at 37°C, washed and added to the responders in standard medium supplemented with 60IU/ml human recombinant interleukin-2 (rIL-2; Eurocetus, Amsterdam, The Netherlands). At day 17, responder cells were harvested on Ficoll-lymphoprep (Nycomed Pharma, Oslo, Norway) and cloned by limiting dilution. Ten or less responder cells were cocultured with 1 X10 5 irradiated (3000rad) PBMC and 5000 irradiated (10000 rad), peptide sensitized washed B-LCL (from at least two different HLA-A*020l-positive donors) in 100 nj standard medium containing 60 IU rIL-2/ml and 1% leucoagglutinin (Phytohaemagglutinin-leucocytes; Sigma, St Louis, Missouri, USA). Growing clones were expanded but stimulated with peptide-sensitized washed B-LCL at a 2-week interval only.
Results
Selection of conserved HIV peptides with binding ability for HLA-A*0201
Analysis of binding to HLA-A*0201 of the amino-acid sequences of Env, Gag, Pol, Rev, Vpu, Vif, Vpr, Tat concentration of peptide, pmol/ml FACscan analysis showed that the clones were CD8-positive. Blocking studies with anti-CD8 or anti-HLA class I antibodies revealed that CTL activity was mediated by CD8+ T cells and was HLA class-1-restricted (data not shown).
The clones were tested at different effector-to-target cell (E:T) ratios to estimate the cytolyn'c capacity. At an E :T ratio of 0.015 for clone 267-18 and 0.15 for clone 468-22, T2 cells sensitized with 5nm/ml of peptide are specifically lysed (data not shown).
The fine specificity of clone 267-18 was studied by serine and arginine replacements in the synthetic Pol267_277 peptide. Binding of the peptide was strongly influenced by the residues at position 2 and 11. Replacement by a small amino acid such as serine showed that residues 3, 4, 5, 8 and 9 in particular are important for recognition by the CTL. Arginine replacement had more drastic effects in that only a replacement at position 6 allowed recognition of peptide-sensitized target cells (data not shown).
Thus, residues at positions 3, 4, 5, 8, 9 and 10 interfere with recognition by the T-cell receptor.
Recombinant vaccinia virus-infected target cells
To investigate whether the clones would not only recognize synthetic peptide but also the naturally processed peptide, the most sensitive CTL clones were tested against B-LCL infected with the recombinant vaccinia viruses wRT or wLacZ. Clones 468-22 and 267-18 lysed wRT but not wLacZ-infected B-LCL (Fig. 2a) . In the same experiments both clones specifically lysed peptide-sensitized HLA-A*0201-matched B-LCL (Fig.  2b) .
Discussion
The therapeutic potential of CTL against tumours and viruses has recently been reviewed [1, 12, 13, 44] . The imminent escape of HIV-1 from deteriorating humoral and cellular immune responses requests prompt and specific intervention. Evoking CTL to highly conserved HIV-1-derived epitopes may decrease the risk of emerging escape mutants of HIV-1, which may contribute to the control of HIV-1 infection.
Following our strategy to screen protein sequences for potential CTL epitopes, test selected peptides for MHC class I binding, and induce CTL against the optimally binding peptides resulted in CTL recognizing naturally processed HIV-1-derived peptides, including one novel RT epitope in a protein sequence crucial for RT activity. . The resulting CD8+ CTL clones were able to recognize target cells pulsed with as little as 10 pmol peptide/ml. Observations in mice of CTL against influenza nucleoprotein showed recognition of peptide at concentrations of 0.1-100 pmol peptide/ml [2, 3] .
Clones 468-22 and 267-18 both directed to RT epitopes were able to specifically kill recombinant vaccinia HIV-1 RT-infected targets in a class I-restricted fashion. Although 5'Cr release is lower it is frequently observed that the lower peptide concentration displayed at the cell surface following endogenous processing is often associated with lower 51 Cr-release values than following incubation with much higher doses of exogenous peptide. In a recent study from our laboratory [53] , low in vitro tumour lysis values following incubation with tumour-specific CTL was nevertheless associated with CTL-mediated protection against tumour outgrowth in vivo [53] . Thus, the lower CTL response measured in vitro against the endogenously processed peptide provided adequate protection in vivo [53] . An overall difference in the maximum percentage of lysis can be noticed between clones 267-18 and 468-22. This could be due to a difference in lytic capability of the clones although both clones lysed their targets at similar E : T ratios. The lysis of wRT-infected cells is similar when compared with the background lysis of wLacZ-infected cells. On the other hand, variation in peptide affinity can exist between different CTL recognizing the same epitope [2, 3] .
It will be of interest to study the possible diversity of the T-cell repertoire against epitope Pol267-277-Sequences in which no variation is allowed due to functional or structural constraints on the viral protein may offer CTL an opportunity to attack HIV-1 at its Achilles' heel. The RT-derived peptide Pol267~277 "^Y therefore be a particularly interesting epitope. Site-specific mutagenesis of the region overlapping peptide Pol267-277 revealed that alterations in the sequence by substitution of single amino acids at position 269 (asp to glu}, 272 (asp to gly) or 273 (ala to ser) can profoundly affect RT activity [54] . All of these amino acids are located in peptide Pol267_277-The amino-acid replacement study showed that among six of the amino-acid side chains the aspartic acid at position 269 was also important for recognition by clone 267-18. The amino acids at positions 3, 4, 5, 8, 9 and 10 seem essential for T-cell receptor recognition, which largely confirms previous reports on HLA-A*0201-restricted CTL [8, 34, 55] . Viral escape from T-cell recognition by mutation of the T-cell receptor contact residues [28,56] could be disastrous for the virus in the case of the Pol267_277 epitope.
Recently Harrer et al. [24] reported a study of anti-HIV CTL responses in long-term asymptomatic HIVseropositive individuals. A response was found against a CTL epitope that spans the RT region of the highly conserved YMDD amino-acid motif also known to be important for RT function [54, 57] . Targeting the immune response to this epitope, the epitope identified in this study and others found in regions that are functionally important for the life cycle of HIV-1 may influence the length of the asymptomatic phase.
Our data show the feasibility of primary in vitro targeting to a synthetic viral peptide of human CTL capable of recognizing the naturally processed peptide. Recently, induction of primary CTL in a completely autologous system was reported [52] . These approaches may allow in vitro culture of CTL against a viral or autologous peptide of interest for adoptive transfer into patients with viral disease or cancer. Primary CTL induction with lymphocytes obtained from HIV-infected subjects has to be established. We are currently investigating this possibility with PBMC obtained from long-term asymptomatic patients.
A study by Sijts et al. [58] in mice showed the relevance of cryptic epitopes: upon infection with the Moloney sarcoma virus-murine leukaemia virus complex C57BL/6 mice (H2b) respond with a class I D>>-restricted CTL response but peptide vaccination with a Kb-restricted epitope resulted in CTL recognizing this epitope both as synthetic peptide and as endogenously processed antigen in the context of K^. It is therefore feasible to direct the cellular immune response to subdominant epitopes that are not selected as major epitopes for CTL recognition. It can be argued that immunization with peptides might result in relatively low responses in vitro and that peptide immunization might therefore result in weak responses in vivo. However, in vivo peptide immunization could result in higher levels of specific CTL because the proper cytokine networks and lymphoid architecture are available. In animal models it has been shown that peptide immunization can effectively protect against lymphocytic choriomeningitis virus [9] , Sendai virus [7] and human papilloma virus-induced tumours [53] . A peptide-based vaccine also elicited protective CTL in rhesus monkeys against SIV [59] .
The exquisite sensitivity of CTL to sequence variation in the epitope itself demonstrates the need for stable epitopes. Thus peptide vaccines should be designed to evoke immune responses against several of these functionally important epitopes in order to minimize the emergence of escape variants of the virus.
